Primary alpha-sarcoglycan deficiency responsive to immunosuppression over three years

Area of Science:

• Neurology
• Genetics
• Immunology

Background:

• Limb-girdle muscular dystrophies (LGMDs) are a heterogeneous group of inherited muscle disorders.
• Primary alpha-sarcoglycan deficiency (LGMD2D) is a rare form of LGMD, often presenting in childhood with progressive muscle weakness.
• The role of inflammation in LGMD pathogenesis is increasingly recognized, prompting investigation into immunomodulatory therapies.

Observation:

• An 8-year-old female presented with a 2-year history of progressive muscle weakness and elevated creatine kinase.
• Muscle biopsy revealed active myopathy with significant inflammatory cell infiltration.
• Initial treatment involved a trial of immunosuppression using prednisone.

Findings:

• Within 2 months of prednisone treatment, the patient demonstrated marked functional and quantitative improvement in proximal muscle strength.
• Strength gains were maintained over a 3-year follow-up period.
• Genetic analysis confirmed the diagnosis of primary alpha-sarcoglycan deficiency.

Implications:

• This case suggests that immunosuppressive therapy may be beneficial in managing certain forms of muscular dystrophy, even those with a primary genetic defect.
• The observed treatment response in alpha-sarcoglycan deficiency is comparable to that seen in Duchenne muscular dystrophy patients treated with corticosteroids.
• Further research is warranted to explore the efficacy and mechanisms of immunosuppression in genetically defined muscular dystrophies.